Premium
Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults
Author(s) -
Patruno Cataldo,
Stingeni Luca,
Hansel Katharina,
Ferrucci Silvia Mariel,
Tavecchio Simona,
Fabbrocini Gabriella,
Nisticò Steven Paul,
Foti Caterina,
De Prezzo Serena,
Napolitano Maddalena
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.13290
Subject(s) - dupilumab , atopic dermatitis , eczema area and severity index , medicine , dermatology life quality index , dermatology , quality of life (healthcare) , psoriasis , nursing
Nummular eczema (NE) is currently considered as one of the clinical phenotypes of atopic dermatitis (AD) of the adult. In this multicentre study, 30 adult patients (age ≥ 18 years) affected with nummular‐like AD were treated with dupilumab, a monoclonal antibody against the receptor for interleukin(IL)‐4 and IL‐13. The evaluation of the results after 16 weeks of treatment showed a significant improvement of the disease, as demonstrated by reduction in Eczema Area Severity Score (EASI), visual analogue score (VAS) of pruritus, and Dermatology Life Quality Index (DLQI) scores. Conjunctivitis in one patient was the only side effect. In conclusion, dupilumab seems to be an effective and safe treatment in NE phenotype of AD of the adult.